Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response
Links shared publicly online about this topic.
- 1,774total visits
Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immune response
View full resource at news-medical.net
Tags: Immune, Vaccination, Flu, H1N1, Clinical Trial, Vaccine, Novartis
Most Recently Shared on September 4, 2009 at 6:58 am By:
H1N1 Swine Flu News: Clinical trial of Novartis MF59 swine-flu vaccine elicits a strong immu.. http://twurl.nl/pimffl
Novartis MF59 adjuvanted cell culture-based vaccine shows strong immune response in A(H1N1) clinical trials
novartis.com — “Basel, September 3 2009 - A pilot trial of Novartis adjuvanted cell culture-based A(H1N1) vaccine[1] indicates that the swine flu vaccine elicited a strong immune response and was well tolerated. The trial was run by the UK's University of Leicester and University Hospitals of Leicester. The vaccine, to be called Celtura, was tested with 100 healthy volunteers, aged between 18 and 50.” View full resource at novartis.com
Most Recently Shared on September 15, 2009 at 2:47 pm By:
eyeonfda Pharma and Health Lawyer
Novartis MF59® adjuvanted cell culture-based vaccine immune response in A(H1N1) clinical trials http://bit.ly/1ymk28
Advertisement
